Abstract
We present a case of delayed-type hypersensitivity to hyaluronic acid (HA)-based
filler on the face following the Pfizer booster in a Moderna-vaccinated
individual. It is the first known case of treatment of the delayed-type
hypersensitivity reaction with hyaluronidase following Covid vaccination.
Hyaluronidase is a viable option to treat this reaction, particularly for
patients who may not benefit from systemic treatment options. With an
anticipated fourth round of vaccine boosters on the horizon, there may be an
increased incidence of cutaneous adverse events, including the reaction
discussed.